NICE to consider lenalidomide maintenance treatment for myeloma patients post high dose therapy and stem cell transplantation

Lenalidomide (Revlimid®) maintenance for myeloma patients who have undergone high dose therapy and stem cell transplantation (HDT-SCT) will be considered for use on the NHS by The National Institute for Health and Care Excellence (NICE) later this year. This announcement comes after updated advice from the manufacturer Celgene and follows publication of data from the Myeloma XI clinical…

Details

Daratumumab combinations are effective for the treatment of newly diagnosed myeloma.

Results from two phase III clinical trials (MAIA and CASSOPIEA) evaluating daratumumab (Darzalex®) combinations for the treatment of newly diagnosed myeloma patients have been recently published. The data provide evidence to support the use of daratumumab for the treatment of newly diagnosed myeloma patients whether they are eligible for high dose therapy and stem cell…

Details

Highlights from the 2019 UK Myeloma Forum Scientific Workshop

The UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…

Details